Harnessing complex metabolic signatures to predict drug efficacy in ovarian cancer

Abstract

"Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)"